30.95USD-1.31%Mkt Cap: 1.46B USDP/E: —Last update: 2026-06-01
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidat…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.46B USD
Enterprise Value1.06B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-86.97M USD
Revenue/Share—
Last Price30.95 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.98
PEG—
EV/EBITDA-10.74
EV/Revenue—
P/S—
P/B3.42
EPS (TTM)-2.17
EPS (Forward)-3.94
52W Range
9.43059% of range45.85
52W High45.85 USD
52W Low9.430 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.56%
ROA-22.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-79.95M USD
CapEx (TTM)1.93M USD
FCF Margin—
FCF Yield-3.59%
Net Debt-439.42M USD
Net Debt/EBITDA4.46
Balance Sheet
Debt/Equity0.00
Current Ratio30.79
Quick Ratio30.42
Book Value/Sh9.202 USD
Cash/Share9.244 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)69.09 USD
Target Range20.00 USD – 91.00 USD
# Analysts11
Ownership
Shares Out.47.60M
Float29.61M
Insiders2.70%
Institutions111.45%
Short Interest
Short Ratio6.8d
Short % Float12.63%
Short % Out.9.00%
Shares Short4.28M
Short (prev mo.)3.79M
Technical
SMA 5031.78 (-2.6%)
SMA 20027.08 (+14.3%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)608.05K
Avg Vol (10d)582.29K
Technical Indicators
RSI (14)46.3
MACD-0.2623
MACD Signal0.0778
MACD Hist.-0.3401
BB Upper39.87 USD
BB Middle33.09 USD
BB Lower26.30 USD
BB Width41.00%
ATR (14)2.332 USD
Vol Ratio (20d)0.43x